Chorionic Villus Sampling for Rapid Confirmation of High‐Risk NIPT Results for Trisomy 21, 18, and 13
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2025. Verfasst von Malgorzata I Srebniak und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Chorionic Villi Sampling, Down Syndrome, Trisomy 13 Syndrome, Trisomy 18 Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
International societies recommend amniocentesis (AC) after high‐risk non‐invasive prenatal testing (NIPT) because of potential inconclusive results from chorionic villus sampling (CVS) caused by placental mosaicism. Our study aimed to evaluate the necessity of confirmatory amniocentesis following CVS for trisomies 21, 18, and 13 with separate analysis of cytotrophoblast (CTB) and mesenchymal core (MC).
Methods
We retrospectively analyzed the confirmatory cytogenetic results between April 2017 and December 2022. CTB and MC were separated and analyzed by QF‐PCR and/or SNP array, and karyotyping when needed.
Results
Among 338 cases, 70% (237/339) of women underwent CVS (70.5%) and 30% (101/338) underwent AC. Mosaic trisomy in MC requiring additional amniocentesis was detected in 13.5% (5/37) of cases referred due to trisomy 13, 2.5% (4/158) of cases of trisomy 21% and 0% (0/42) of cases of trisomy 18.
Conclusions
A definitive diagnosis of CVS was achieved in 97.5%, 100%, and 86.5% of patients with high‐risk NIPT results for trisomy 21, 18, and 13, respectively. Moreover, our clinical practice confirms that the majority of pregnant women (70%) opted for CVS as a quick confirmatory test. We conclude that both CVS and AC can be offered when preceded by pre‐test counseling on the risks of potential inconclusive results as calculated in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genetics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
- Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
- Department of Gynecology, Amphia Hospital, Breda, the Netherlands.
- Department of Obstetrics and Gynecology, Reinier de Graaf Gasthuis, Delft, the Netherlands.
- Department of Obstetrics and Gynecology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
ORCID-Profile: Malgorzata I Srebniak, Philip L J DeKoninck, Karin E M Diderich, Diane Van Opstal
Zitieren
APA
Srebniak, M. I., Weerts, M., Joosten, M., Drost, M., Galjaard, R. J., van der Schoot, V., van den Born, M., Knapen, M. F. C. M., Prinsen, K., Cornette, J. M. J., DeKoninck, P. L. J., Papatsonis, D., Spaan, J., Dijkman, A., de Weerd, S., Go, A. T. J. I., Diderich, K. E. M., & Van Opstal, D. (2025). Chorionic Villus Sampling for Rapid Confirmation of High‐Risk NIPT Results for Trisomy 21, 18, and 13. Prenatal Diagnosis. https://doi.org/10.1002/pd.6837
Vancouver
Srebniak MI, Weerts M, Joosten M, Drost M, Galjaard RJ, van der Schoot V, et al. Chorionic Villus Sampling for Rapid Confirmation of High‐Risk NIPT Results for Trisomy 21, 18, and 13. Prenatal Diagnosis. 2025. doi:10.1002/pd.6837
BibTeX
@article{Srebniak2025,
author = {Srebniak, Malgorzata I and Weerts, Marjolein and Joosten, Marieke and Drost, Mark and Galjaard, Robert Jan and van der Schoot, Vyne and van den Born, Myrthe and Knapen, Maarten F C M and Prinsen, Krista and Cornette, Jerome M J and DeKoninck, Philip L J and Papatsonis, Dimitri and Spaan, Julia and Dijkman, Anneke and de Weerd, Sabina and Go, Attie T J I and Diderich, Karin E M and Van Opstal, Diane},
title = {Chorionic Villus Sampling for Rapid Confirmation of High‐Risk NIPT Results for Trisomy 21, 18, and 13},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6837}
}
EUVIMED